Pharmaceuticals

AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Inc. (NYSE: ABBV) is trading lower on Tuesday, December 16, 2025, after a strong run earlier in the quarter and a Monday close that kept the stock near the upper end of its 52‑week range. As of 17:54 UTC

16 December 2025

Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck & Co., Inc. (NYSE: MRK) stock was among the biggest drags on the Dow Jones Industrial Average in Tuesday’s session (December 16, 2025), with shares trading lower as investors weighed broad market pressure alongside a fast-moving set of company-specific

16 December 2025

Drug Patents · Investment Analysis · Merck Updates · NYSE:MRK · Pharma Industry · Stock Market News

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

December 16, 2025 — GSK plc stock (LSE: GSK; NYSE: GSK) is firmly on investors’ radar today after a cluster of late-year regulatory catalysts across respiratory, vaccines, and infectious diseases — the kind of headline flow that can reshape sentiment

16 December 2025

FDA Updates · Investment News · NYSE:GSK · Pharmaceuticals · Stock Market · UK Regulatory Approvals

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts

15 December 2025

Biotech Forecasts · FDA Updates · Investment Analysis · NYSE:GSK · Pharma News · Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has quietly turned into one of 2025’s wildest biotech comeback stories. After years as a perpetually “promising” RNA interference (RNAi) platform, the company now has: The stock price has responded in full drama mode. As of

11 December 2025

Biotechnology · FDA Approvals · Investment Analysis · Pharmaceutical Industry · Stock News

Teva Pharmaceutical Industries (TEVA) Stock: FDA Filing, Analyst Upgrades and 2026–27 Outlook on December 10, 2025

December 10, 2025 – New York / Tel Aviv Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) is trading around its 52‑week highs as a wave of fresh news hits the stock: a new U.S. FDA filing for a once‑monthly

10 December 2025

FDA News · Financial Outlook · Investment Analysis · NYSE:TEVA · Pharmaceuticals · Stock Market

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is back on traders’ radar as a late‑stage CNS biotech preparing for a potential New Drug Application (NDA) in schizophrenia while its stock trades under $1 and analysts publish double‑ and even triple‑digit upside

10 December 2025

Financial Forecast · Investment News · NASDAQ:RVPH · Pharmaceuticals · Schizophrenia · Stock Market

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company (NYSE: LLY) is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about

9 December 2025

Drug Developments · Investment Insights · Market Outlook · NYSE:LLY · Pharma News · Stock Analysis

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

As of 9 December 2025, GSK plc (LSE: GSK; NYSE: GSK) stock is trading close to its 52‑week highs on both sides of the Atlantic, after a year in which the UK pharma group has upgraded guidance, accelerated buybacks and

9 December 2025

Company Analysis · Financial News · Investment Strategies · NYSE:GSK · Pharmaceuticals · Stock Market

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached

8 December 2025

Biotech News · Healthcare Policy · Investment Analysis · Pharmaceuticals · Stock Market

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something

8 December 2025

Artificial Intelligence · Biotechnology · Clinical Trials · Pharmaceuticals · Stock Analysis

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

Recursion Pharmaceuticals (NASDAQ: RXRX), one of the highest‑profile AI‑driven drug discovery names, is back under the microscope. As of the December 5, 2025 close, RXRX stock traded around $4.71, giving the company a market capitalization of roughly $2.5 billion and

7 December 2025

CEO Changes · Insider Activity · Market Outlook · NASDAQ:RXRX · Pharma News · Stock Analysis